Kenjiro Kishitani

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery.

Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: May 04, 2026

Multiple Cranial Neuropathies After Lenvatinib-Pembrolizumab Therapy for Metastatic Renal Cell Carcinoma: A Case Report.

Multiple Cranial Neuropathies After Lenvatinib-Pembrolizumab Therapy for Metastatic Renal Cell Carcinoma: A Case Report.

Journal: IJU case reports

Published: October 25, 2025

A validation of height- and body mass index-adjusted skeletal muscle Z-scores for cancer prognosis prediction.

A validation of height- and body mass index-adjusted skeletal muscle Z-scores for cancer prognosis prediction.

Journal: Clinical nutrition ESPEN

Published: February 14, 2025

Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.

Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: September 21, 2024

Survival improvement over time in renal cell carcinoma treated with nephrectomy: A longitudinal propensity score-matched study.

Survival improvement over time in renal cell carcinoma treated with nephrectomy: A longitudinal propensity score-matched study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: July 09, 2024

Integrated impact of multiple body composition parameters on overall survival in gastrointestinal or genitourinary cancers: A descriptive cohort study.

Integrated impact of multiple body composition parameters on overall survival in gastrointestinal or genitourinary cancers: A descriptive cohort study.

Journal: JPEN. Journal of parenteral and enteral nutrition

Published: March 15, 2024

The importance of ethnic-specific cut-offs of low muscle mass for survival prediction in oncology.

The importance of ethnic-specific cut-offs of low muscle mass for survival prediction in oncology.

Journal: Clinical nutrition (Edinburgh, Scotland)

Published: October 10, 2023

Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.

Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 02, 2023

Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.

Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.

Journal: Immunotherapy

Published: May 16, 2023

Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report.

Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report.

Journal: BMC urology

Published: October 25, 2022

Left-right reversal of the testes within the scrotum: An extremely rare variant of testicular ectopia.

Left-right reversal of the testes within the scrotum: An extremely rare variant of testicular ectopia.

Journal: IJU case reports

Published: August 27, 2022

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.

Journal: BMC urology

Published: June 21, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026